Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen

@inproceedings{Helmschrott2014SuperiorRP,
  title={Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen},
  author={Matthias Helmschrott and Jan Christian Beckendorf and Ceylan Akyol and Arjang Ruhparwar and Bastian Schmack and Christian Erbel and Christian A. Gleissner and Mohammadreza Akhavanpoor and Philipp Ehlermann and Tom Bruckner and Hugo A. Katus and Andreas O. Doesch},
  booktitle={Drug design, development and therapy},
  year={2014}
}
BACKGROUND The use of tacrolimus (TAC) in patients after heart transplantation (HTX) has increased over the last few years. AIM In this retrospective study, we evaluated the effects of a TAC (conventional and extended-release TAC)-based immunosuppressive therapy regarding rejection profile in comparison to a cyclosporine A (CSA)-based regimen in patients after HTX. METHODS The data of 233 patients who underwent HTX at the Heidelberg Heart Transplantation Center from May 1998 until November… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

Similar Papers

Loading similar papers…